David Nabarro, British physician who led UN response to Ebola and COVID-19, dies
Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, confirmed Nabarro's death on social media platform X.
'David was a great champion of global health and health equity, and a wise, generous mentor to countless individuals,' Tedros wrote Saturday. 'His work touched and impacted so many lives across the world.'
King Charles knighted Nabarro in 2023 for his contributions to global health after he served as one of six special envoys to the WHO on COVID-19. He won the 2018 World Food Prize for his work on health and hunger issues.
He also was a candidate for the top job at the WHO in 2017 but lost out to Tedros in the final round of voting. Nabarro left the U.N. later that year.
The 4SD Foundation, a social enterprise in Switzerland focused on mentoring the next generation of leaders in global sustainable development, said its strategic director died at his home Friday in a 'sudden passing.' Other details were not immediately available.
'David's generosity and unwavering commitment to improve the lives of others will be sorely missed,' the foundation wrote on its website Saturday.
Survivors include his wife, Flo, as well as his five children and seven grandchildren.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Clinical Case: Kidney Cancer Hides in 6-mm Breast Lesion
A 54-year-old woman with a history of renal cell carcinoma (RCC) developed a metastatic lesion in her breast 6 years after radical nephrectomy. The lesion, initially detected via routine imaging, was confirmed as RCC by histopathology and immunohistochemistry. This case report by Aman Saswat Sahoo, a fourth-year Medicine & Surgery undergraduate at the University of Central Lancashire, School of Medicine and Dentistry, Preston, England, and colleagues, highlighted the need for meticulous diagnostic evaluation to distinguish between primary breast carcinoma and metastatic disease, particularly in patients with a history of RCC. The Patient and Her History The patient had a history of RCC that was initially treated with radical nephrectomy and no chemotherapy. She had undergone regular CT imaging since her surgery 3 years ago, and routine CT identified a 4-mm lesion in the lower outer quadrant of the right breast. No other relevant preexisting medical conditions were reported. Her medical, family, travel, allergy, social, and drug histories were unremarkable. Findings and Diagnosis A clinical examination revealed no palpable abnormalities in both breasts. Mammography revealed a 6-mm nodule in the posterolateral region of the right breast, which was absent on a prior mammogram conducted 4 years earlier. Ultrasound imaging confirmed the presence of a solid nodule measuring approximately 5 mm in size. Ultrasound evaluation correlated these findings with a 5-mm benign-appearing nodule. A core biopsy was performed, and histopathologic evaluation showed an inflammatory lesion, characterised by cells with clear cytoplasm and macrophages. Considering the initial diagnosis, immunohistochemical staining provided crucial diagnostic clarity, with positive results for PAX8, CD10, and MNF116 markers, confirming metastatic RCC. Given the patient's history, these findings confirmed the presence of metastatic RCC in the right breast. The patient was informed of the diagnosis of metastatic RCC in the right breast. Further assessment of distant sites and the potential for systemic therapy were discussed at this stage; however, it was later decided that no systemic interventions would be pursued. Although the lesion was considered minor in terms of surgical intervention, its identification is crucial as an indicator of metastatic disease. Wide local excision was performed after tagging the lesion with a radiofrequency identification tag located 3 mm inferior to the original site; no axillary surgery was performed. Postoperative histopathologic evaluation revealed a 5-mm well-circumscribed metastatic RCC. No vascular invasion, ductal carcinoma in situ, or lobular carcinoma in situ was identified. Discussion Although RCC is prominent in its ability to spread haematogenously, metastasis to the breast is extremely uncommon. The route for metastasis usually includes the migration of tumour cells from the kidneys through the inferior vena cava to the right ventricle of the heart. From here on, they enter the pulmonary circulation and eventually reach the breast. Breast metastasis from RCC is exceedingly rare, with fewer than 60 cases documented in the literature. Although the risk for RCC recurrence is highest within the first 2 years following treatment, metastases to uncommon sites, such as the breast, have been reported even a decade after the initial diagnosis and surgical intervention. 'The limited information available in the literature regarding optimal treatment strategies and patient outcomes for RCC metastasis to the breast highlights the need for further studies to better understand this condition,' the authors wrote.
Yahoo
2 hours ago
- Yahoo
Resident doctors strike in the face of a tiring public
Up to 50,000 NHS resident doctors are currently on strike over pay, their twelfth walkout since March 2023. So what? This month Labour announced an ambitious plan meant to revive a health service that is on its knees. Any detail from that has now been overtaken by a downing of tools that will severely disrupt medical treatments; could encourage similar action by nurses; and may lead to patient deaths. Here we go again. Ending resident doctor strikes was one of the health secretary Wes Streeting's first priorities. Last year he struck a deal with the British Medical Association to increase pay by 22 per cent. This was a temporary boost, since it only applied to 2023-25 salaries. For 2025-26, the rise was 5.4 per cent. Not good enough. This is better than the 3.6 per cent pay rise awarded to nurses in June 2025. But the BMA wants full 'pay restoration'. It says the salaries of resident doctors, who are still in training, are 21 per cent lower in real terms than in 2008 because of inflation. Damned statistics. The BMA uses the Retail Price Index (RPI) to reach this number. The government uses another measure, the Consumer Price Index (CPI). This is the official metric used to calculate changes to the cost of living, based on a basket of consumer goods. If CPI is used, pay has only fallen by 4.7 per cent since 2008, according to the Nuffield Trust. Hang on. The BMA's insistence on using RPI is based, in part, on the fact that the government uses it to calculate rail fares and interest payments on student debt. The latter is particularly relevant. Although they earn a relatively high salary after 5 years in training (£61,825 a year, excluding compulsory overtime), doctors emerge from five years of medical school owing as much as £100,000. Ouch. That's nearly double the average debt pile of British graduates. Unlike many other professionals, medical trainees also spend thousands of pounds on exam fees and courses. Another thing. Pay isn't the only grievance, with resident doctors also complaining about a shortage of speciality training posts, which means many get stuck on the middle rungs of the career ladder; an arcane placement system that requires them to move around the country at a few months' notice; and gruelling hours and stressful working conditions. Cash-strapped. This time round, the health secretary is less sympathetic and says there is no more money for pay rises. Last year's increases ate up more than half of the extra £10.4 billion given to the NHS. Streeting would rather be getting on with plans to revamp the health system. These are centred around shifting care from hospitals to the community; making better use of digital tech; and preventing sickness in the first place. Shifting opinions. The public seems to be on his side. In 2024, more than half of Brits supported strike action by trainee doctors. This has fallen to 32 per cent. The head of the Royal College of Nursing has said it is 'grotesque' to hand doctors bigger increases than nurses. Negotiations. In an unsuccessful bid to avert the strikes, Streeting made several last-minute offers, including accelerating doctors' training so they progress through the pay scales faster; giving them part of their pensions upfront; and subsidising exam fees. The toll. Previous rounds of strikes led to the cancellation of 1.5 million planned appointments, as well as five deaths. Labour is eager to avert more cancellations, having made much of bringing down waiting lists. NHS England has not postponed scheduled non-urgent care. What's more… The BMA has criticised this decision, saying it puts lives at risk. Critics have pinned the responsibility on them, saying they chose to strike. Either way, patients will suffer.
Yahoo
2 hours ago
- Yahoo
COVID-19 cases are on the rise in MA, CDC says. What to know about 'Nimbus' strain.
COVID-19 numbers are rising in Massachusetts, and in states across the country. "COVID-19 laboratory percent positivity is increasing nationally," according to the Centers for Disease Control and Prevention (CDC) website. "Emergency department visits for COVID-19 are increasing among young children 0-4 years old," though the CDC noted that emergency room visits are "low" overall. The latest COVID-19 strain is known as "Nimbus." Here's what to know. Are COVID-19 numbers increasing in Massachusetts? The CDC website has evaluated the issue in each state and determined cases in Massachusetts are likely rising. In Massachusetts, there is an 85.8% chance that COVID-19 numbers are increasing, according to the CDC. The Massachusetts Department of Public Health (DPH) reported that as of June 28, there were 377 confirmed cases of COVID and 77 unconfirmed cases. No COVID-19 deaths were reported at the time. The data stops in June because the Massachusetts DPH "ended data collection for the 2024-2025 viral respiratory season on June 28, 2025, and routine updates to their dashboard for the 2025-2026 season will resume later this summer." What is the current COVID-19 strain 'Nimbus?' As of early June, the new strain known as NB.1.8.1, or "Nimbus," made up 37% of COVID-19 cases nationwide. Variant NB.1.8.1 was first detected in China in January 2025 but accounted for about 0% of cases in the United States until May. The World Health Organization added at the time that currently approved COVID-19 vaccines are "expected to remain effective to this variant against symptomatic and severe disease." Virologists describe Nimbus as a 'slightly upgraded' version of its predecessor. While there is no evidence it causes more severe disease, it appears to be highly transmissible. What are the symptoms of Nimbus? Reported symptoms of NB.1.8.1 are similar to other COVID-19 strains, but one distinctive complaint is a severe sore throat, sometimes described as 'razor-blade throat fatigue.' Other symptoms may include: Mild cough Fever Muscle aches Nasal congestion Are vaccines still effective? Health experts say that updated COVID-19 vaccines remain the best protection against severe illness. Vaccination rates vary widely by state, and health officials continue to urge eligible individuals to stay current with their shots. How can people get tested? People can either take an at-home test or they can see their respective doctors. (This story was updated because an earlier version included an inaccuracy.) This article originally appeared on COVID cases on rise in MA, CDC says. What to know about latest strain Solve the daily Crossword
